We are always introducing new clinical trials across our international network. If you can’t find what you are looking for please don’t hesitate to speak to your doctor to learn more, or contact us here.
Find a trial
At Icon, we offer clinical trials across various tumour types and blood disorders, allowing patients access to new and emerging advances in treatment, find a trial that might be suitable for you.
Use the search function below to find a clinical trial that may suit you and your cancer diagnosis
ADG206-1001
A First-in-Human (FIH), Open-Label, Phase 1 Study of ADG206, a CD137 Agonist Antibody, in Subjects with Advanced/Metastatic Solid Tumors
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
SKB264-II-06
A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Locations
Wesley
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
SHR-A1921-I-102
A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1921 in Subjects With Advanced Malignant Solid Tumour .
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
BGB-A317-26808-101
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
BGB-24714-101
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and in Combination With Chemotherapy in Patients With Advanced or Metastatic Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
RC198-G001
A Phase 1, First-In-Human, Multicenter, Open-Label Study in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Locations
Wesley
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
IL Believe
A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination With Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Locations
Farrer Park
Diagnosis
Advanced solid tumours, Cervical cancer, Lung cancer, Skin cancer – melanoma
Open for recruitment
View Trial
BBI-TP-3654-102
A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-3654 in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis
Locations
Adelaide (Windsor Gardens)
Diagnosis
Myeloproliferative disorders
Open for recruitment
View Trial
PXS5505-MF-101
A Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Postpolycythemia Vera or Post-essential Thrombocythemia Myelofibrosis
Locations
Adelaide (Kurralta Park)
Diagnosis
Myeloproliferative disorders
Open for recruitment
View Trial
DB-1303-O-1001
A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients With Advanced/Metastatic Solid Tumors. (DB-1303-O-1001)
Locations
South Brisbane
Diagnosis
Breast cancer, Endometrial cancer
Open for recruitment
View Trial
BGB-A317-A3055-101
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
AK127-101
A Phase 1a/1b, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumour Activity of AK127 in Combination With AK104 in Subjects With Advanced or Metastatic Solid Tumours
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
STARSTRUCK 177Lu-TLX250-001
A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and peposertib in Patients with Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
HMDB-001-003
A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-small Cell Lung Cancers
Locations
South Brisbane
Diagnosis
Lung cancer
Open for recruitment
View Trial
HMDB-001-002
A Phase 1b Study to Evaluate HMBD-001 With or Without Chemotherapy in Participants With Advanced Solid Tumors Harboring NRG1 Gene Fusions or Selected HER3 Mutations
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
ZN-c3-005
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (ZN-c3-005/GOG-3066/DENALI)
Locations
Chermside
Diagnosis
Ovarian cancer
Open for recruitment
View Trial
BA3011-002
A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on a PD-1/L1, EGFR, or ALK Inhibitor
Locations
Central Building (Oncology)
Diagnosis
Lung cancer
Open for recruitment
View Trial
ASPEN-06 AT148006
A Phase 2/3 Study of ALX148 in Patients with Advanced HER2- Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)
Locations
Southport
Diagnosis
Gastric / gastroesophageal cancer
Open for recruitment
View Trial
OLYMPIA-3 R1979-ONC-2105
A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (O-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)
Locations
Wesley
Diagnosis
Lymphoma – B-cell Non Hodgkin’s
Open for recruitment
View Trial
OLYMPIA-1 R1979-HM-2298
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator’s Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)
Locations
Wesley
Diagnosis
Lymphoma – B-cell Non Hodgkin’s
Open for recruitment
View Trial
Viktoria-1 CELC-G-301
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
Locations
Southport
Diagnosis
Breast cancer
Open for recruitment
View Trial
Viktoria-1
A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy
Locations
Farrer Park
Diagnosis
Breast cancer
Open for recruitment
View Trial
RAMP 301 VS-6766-301
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator’s Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)
Locations
Wesley
Diagnosis
Ovarian cancer
Open for recruitment
View Trial
VERITAC-2 C4891001
A Phase 3, Randomized, Open-Label, Multicenter Trial of ARV-471 (PF-07850327) VS Fulvestrant in Participants with Estrogen Receptor-Positive, HER-2-Negative Advanced Breast Cancer whose Disease Progressed after Prior Endocrine Based Treatment for Advanced Disease (VERITAC-2)
Locations
Hobart, Adelaide (Kurralta Park), Adelaide (Windsor Gardens)
Diagnosis
Breast cancer
Open for recruitment
View Trial
RADIANT BAY 88-8223 / 20510
A Phase 4, Randomized, Open-label, Multicenter Efficacy and Safety Study of Standard Dose of Radium-223 Dichloride vs. Standard Doses of Novel Anti-hormonal Therapy (NAH) in Patients With Bone Dominant Metastatic Castration Resistant Prostate Cancer (mCRPC) Progressing on/After One Line of NAH
Locations
Adelaide (Kurralta Park)
Diagnosis
Prostate cancer
Open for recruitment
View Trial
CS5001-101
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors and Lymphomas
Locations
Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours, Lymphoma – B-cell Non Hodgkin’s, Lymphoma – T-Cell Non Hodgkin’s, Lymphoma – Hodgkin’s
Open for recruitment
View Trial
LM108-01-101
A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
APG-2449-OG-101
A Phase Ib/II Study of APG-2449 in Combination with Doxorubicin Hydrochloride Liposome in Patients with Ovarian Cancer
Locations
South Brisbane
Diagnosis
Ovarian cancer
Open for recruitment
View Trial
CAPTURE BCT1901
A phase II randomised study to evaluate alpelisib plus fulvestrant versus capecitabine in oestrogen receptor positive, HER2-negative advanced breast cancer patients with PIK3CA mutant circulating DNA.
Locations
Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
CO44194
A Phase II, Multicenter, Randomized, Double-Blind Study of RO7247669 Combined with Nab-Paclitaxel compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
Locations
Adelaide (Windsor Gardens)
Diagnosis
Breast cancer
Open for recruitment
View Trial
JAVELIN Bladder Medley MS100070_0119
A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)
Locations
Adelaide (Kurralta Park)
Diagnosis
Urothelial cancer
Open for recruitment
View Trial
BO44157
A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy
Locations
Adelaide (Kurralta Park)
Diagnosis
Urothelial cancer
Open for recruitment
View Trial
CAPItello-280
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Locations
Adelaide (Kurralta Park)
Diagnosis
Prostate cancer
Open for recruitment
View Trial
INAVO122
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Locations
Farrer Park
Diagnosis
Breast cancer
Open for recruitment
View Trial
INAVO121 WO43913
A Phase III, Multicenter, Randomized, Open-Label Study Evaluation the Efficacy and Safety of Inavolisib plus Fulvestrant versus Alpelisib plus Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer who Progressed during or after CDK4/6 Inhibitor and Endocrine Combination Therapy
Locations
Wesley
Diagnosis
Breast cancer
Open for recruitment
View Trial
CAMBRIA-1
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
Locations
Farrer Park
Diagnosis
Breast cancer
Open for recruitment
View Trial
SB221
A Proof-of-Concept Study to Assess the Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients with Platinum-Resistant Ovarian Cancer
Locations
Adelaide (Kurralta Park)
Diagnosis
Ovarian cancer
Open for recruitment
View Trial
BO43936
A Randomized Open Label Phase II Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
Locations
Adelaide (Kurralta Park)
Diagnosis
Kidney cancer
Open for recruitment
View Trial
STELLAR 303
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Locations
Farrer Park
Diagnosis
Colorectal cancer
Open for recruitment
View Trial
EvoPAR-Prostate01 D9723C00001
A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
Locations
Townsville, Chermside, Adelaide (Kurralta Park)
Diagnosis
Prostate cancer
Open for recruitment
View Trial
HLX10-020-SCLC302
A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Locations
Wesley
Diagnosis
Lung cancer
Open for recruitment
View Trial
CL-SBP-101-04
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
Locations
Adelaide (Kurralta Park)
Diagnosis
Pancreatic cancer
Open for recruitment
View Trial
ASCENT-07 GS-US-598-6168
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy
Locations
Hobart, Wesley
Diagnosis
Breast cancer
Open for recruitment
View Trial
C-POST R2810-ONC-1788
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Locations
Southport, Adelaide (Kurralta Park)
Diagnosis
Skin cancer – non-melanoma
Open for recruitment
View Trial
BGB-A317-LBL-007-201
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer
Locations
South Brisbane
Diagnosis
Colorectal cancer
Open for recruitment
View Trial
AK104-212
A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer
Locations
South Brisbane, Chermside
Diagnosis
Lung cancer
Open for recruitment
View Trial
Relativity-106
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer (RELATIVITY-106)
Locations
Farrer Park
Diagnosis
Liver cancer
Open for recruitment
View Trial
ABSK043-101
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
BRIGHTLINE-1
A Study to Compare BI 907828 With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Locations
Adelaide (Kurralta Park)
Diagnosis
Sarcoma
Open for recruitment
View Trial
C4391022
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Locations
Townsville
Diagnosis
Breast cancer
Open for recruitment
View Trial
AML M22
AMLM22/D1: The International Acute myeloid leukaemia (AML) Platform Consortium (IAPC) trial is a randomised, multi-arm study platform to compare the efficacy of experimental therapies versus standard of care in patients with acute myeloid leukaemia in first complete remission.
Locations
South Brisbane, Wesley, Chermside, Southport
Diagnosis
Leukaemia
Open for recruitment
View Trial
REGENERON_ R1979-ONC-1625
An open-label study to assess the anti-tumor activity and safety of REGN1979, an Anti-CD20 X Anti-CD3 bispecific antibody, in patients with relapsed or refractory B-cell non-hodgkin lymphoma
Locations
Farrer Park
Diagnosis
Lymphoma – B-cell Non Hodgkin’s
Open for recruitment
View Trial
VNC-236-101
An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity and Pharmacokinetics of VIP236 Monotherapy in Subjects With Advanced Cancer
Locations
South Brisbane, Adelaide (Kurralta Park)
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
LINKER-MM3 R5458-ONC-2245
An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)
Locations
Wesley
Diagnosis
Multiple myeloma
Open for recruitment
View Trial
CLINCH ATG-022-ST-001
An Open, Multi-center, Phase I Clinical Study of ATG-022 in Patients with Advanced/metastatic Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
ALLG NBCR
Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry
Locations
Wesley
Diagnosis
Leukaemia
Open for recruitment
View Trial
LIBERATE
Clinical registry of focal low dose rate brachytherapy in men with biopsy confirmed low-intermediate risk prostate cancer (LIBERATE)
Locations
Epworth Richmond, Epworth Freemasons, Geelong
Diagnosis
Prostate cancer
Open for recruitment
View Trial
CONSOLE
Conventional or Stereotactic Radiotherapy for the palliation of non-spine bone metastases: A randomised phase III trial.
Locations
Wahroonga, Gold Coast University Hospital, Gold Coast Private, Epworth Richmond, Epworth Freemasons, Mulgrave, Hobart
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
DECREASE TROG 19.06
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA
Locations
Epworth Richmond
Diagnosis
Prostate cancer
Open for recruitment
View Trial
DASL-HiCaP ANZUP1801
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)
Locations
Gold Coast University Hospital, Wahroonga, Gold Coast Private, Southport, Adelaide (Kurralta Park), Hobart
Diagnosis
Prostate cancer
Open for recruitment
View Trial
PHI-101-001
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML
Locations
Wesley
Diagnosis
Leukaemia
Open for recruitment
View Trial
EXPERT BCT1601
EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer (EXPERT)
Locations
Epworth Richmond
Diagnosis
Breast cancer
Open for recruitment
View Trial
ERUPT
External beam Radiotherapy and Urethral strictures in Prostate cancer Treatment (ERUPT)
Locations
Toowoomba
Diagnosis
Prostate cancer
Open for recruitment
View Trial
AMT-116-01
First-in-Human, Phase 1 Study of AMT-116, an Anti-CD44v9 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
AMT-151-01
First-in-Human, Phase 1 Study of AMT-151, an Anti-Folate Receptor Alpha Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Locations
South Brisbane
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
HyperArc Registry VAR-2019-01
HyperArc Registry Study
Locations
Canberra, Greenslopes, Gold Coast Private, Maroochydore
Diagnosis
Brain cancer
Open for recruitment
View Trial
I-MAT MASC 03.18
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
Locations
Hobart
Diagnosis
Skin cancer – non-melanoma
Open for recruitment
View Trial
BOREAS KRT-232-101
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)
Locations
South Brisbane, Wesley
Diagnosis
Myeloproliferative disorders
Open for recruitment
View Trial
MASTERPLAN
MASTERPLAN: A Randomised Phase II Study of MFOLFIRINOX and Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer with High Risk and Locally Advanced Disease
Locations
Gold Coast University Hospital
Diagnosis
Pancreatic cancer
Open for recruitment
View Trial
MRDR
Myeloma and Related Disease Registry
Locations
Wesley, South Brisbane, Chermside, Southport
Diagnosis
Multiple myeloma
Open for recruitment
View Trial
OPTIMA BCT 2202
Optimal personalised treatment of early breast cancer using multiparameter analysis
Locations
Southport, Wesley, Hobart, Adelaide (Kurralta Park), Adelaide (Windsor Gardens)
Diagnosis
Breast cancer
Open for recruitment
View Trial
SLN124-004
Phase 1/2 Study With an Open-label Dose Escalation Phase Followed by a Randomized, Double-blind Phase of SLN124 in Patients With Polycythemia Vera
Locations
Adelaide (Kurralta Park)
Diagnosis
Myeloproliferative disorders
Open for recruitment
View Trial
KRYSTAL-10
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation
Locations
Farrer Park
Diagnosis
Colorectal cancer
Open for recruitment
View Trial
HARMONY R3767-ONC-2011
Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Locations
Hobart
Diagnosis
Skin cancer – melanoma
Open for recruitment
View Trial
ARTISTRY-7 ALKS 4230-007
Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Locations
Wesley
Diagnosis
Ovarian cancer
Open for recruitment
View Trial
KEYNOTE-867 MK-3475-867
Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC)
Locations
Hobart
Diagnosis
Lung cancer
Open for recruitment
View Trial
JSKN033-101
Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and efficacy of JSKN033 in Patients with Advanced or Metastatic Solid Malignant Tumours
Locations
Wesley
Diagnosis
Advanced solid tumours
Open for recruitment
View Trial
ANZadapt
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC (ANZadapt)
Locations
Adelaide (Kurralta Park), Adelaide (Windsor Gardens)
Diagnosis
Prostate cancer
Open for recruitment
View Trial
FIG / TROG 18.06
Prospective, multicentre trial evaluating O-(2-[18F]-fluoroethyl)-L-tyrosine Positron Emission Tomography in Glioblastoma (FET-PET in Glioblastoma)
Locations
Wesley
Diagnosis
Brain cancer
Open for recruitment
View Trial
ASCENT-04 GS-US-592-6173
Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
Locations
Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
ASCENT-03 GS-US-592-6238
Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1
Locations
Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
TREMOR
Safety and effectiveness of frameless linac-based stereotactic radiosurgery on tremor in patients with essential tremor or Parkinson’s disease (TREMOR study)
Locations
Epworth Richmond
Diagnosis
Neurological conditions
Open for recruitment
View Trial
KontRASt-02
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
Locations
Wesley, Southport, Townsville
Diagnosis
Lung cancer
Open for recruitment
View Trial
KEYVIBE-006 MK-7684A-006
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer
Locations
Hobart
Diagnosis
Lung cancer
Open for recruitment
View Trial
SUNRAY-01 J3M-MC-JZQB
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
Locations
Wesley
Diagnosis
Lung cancer
Open for recruitment
View Trial
ROSEND
The ROSEND Trial – A Randomised trial for the treatment of recalcitrant symptomatic rosacea using definitive volumetric modulated arc radiotherapy or standard dermatological treatment
Locations
Revesby, Wahroonga, Gosford
Diagnosis
Skin cancer – non-melanoma
Open for recruitment
View Trial
ABCPro
Trial is evaluating a new online service for managing self-reported symptoms by people with advanced breast cancer.
Locations
Bowen Icon Cancer Centre
Diagnosis
Breast cancer
Open for recruitment
View Trial
TUGETHER BCT2102
Tucatinib together with Pembrolizumab and Trastuzumab: A Phase II, Two-Arm, Non-Comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab (MK-3475) and Trastuzumab in Patients with Pre-Treated Advanced HER2-Positive Breast Cancer
Locations
Hobart
Diagnosis
Breast cancer
Open for recruitment
View Trial
There are no clinical trials currently available
Become a patient
Find out how to become a patient at Icon Cancer Centre, or request more information from your nearest centre.
Download your free Cancer Diagnosis Checklist
Be more informed and have an active role in your care; download 'Questions to Ask Your Doctor After Cancer Diagnosis'.
Care at Icon
At Icon, care is more than just a word. Our cancer care team are here to support you with compassion, knowledge and hope.
Iconic Community
Our patients share their perspective and advice.